UA100232C2 - Кристалічні форми інгібітора glyt1 - Google Patents

Кристалічні форми інгібітора glyt1

Info

Publication number
UA100232C2
UA100232C2 UAA200907731A UAA200907731A UA100232C2 UA 100232 C2 UA100232 C2 UA 100232C2 UA A200907731 A UAA200907731 A UA A200907731A UA A200907731 A UAA200907731 A UA A200907731A UA 100232 C2 UA100232 C2 UA 100232C2
Authority
UA
Ukraine
Prior art keywords
crystalline forms
glyt1
preparation
present
methanone
Prior art date
Application number
UAA200907731A
Other languages
English (en)
Russian (ru)
Inventor
Андре БУБЕНДОРФ
Анетте Дейнет-Вуценовіч
Анетте Дейнет-Вуценович
Ральф Діодоне
Ральф ДИОДОНЕ
Олаф Грассманн
Кай Лінденштрут
Кай Линденштрут
Еммануель Пінард
Эммануэль Пинард
Франціска Е. Рорер
Франциска Э. Рорер
Урс Швіттер
Урс ШВИТТЕР
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA100232(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA100232C2 publication Critical patent/UA100232C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Даний винахід стосується різних кристалічних і аморфної форми [4-(3-фтор-5-трифторметилпіридин-2-іл)-піперазин-1-іл]-[5-метансульфоніл-2-((S)-2,2,2-трифтор-1-метилетокси)феніл]метанону та їх застосування при виготовленні фармацевтичних композицій. Сполуки за даним винаходом придатні для виготовлення ліків, корисних для лікування психозів, болю, нейродегенеративної дисфункції пам'яті й навчання, шизофренії, деменції й інших захворювань, при яких порушені когнітивні процеси, таких як синдроми дефіциту уваги або хвороба Альцгеймера.
UAA200907731A 2006-12-28 2007-12-18 Кристалічні форми інгібітора glyt1 UA100232C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (1)

Publication Number Publication Date
UA100232C2 true UA100232C2 (uk) 2012-12-10

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907731A UA100232C2 (uk) 2006-12-28 2007-12-18 Кристалічні форми інгібітора glyt1

Country Status (33)

Country Link
US (5) US20080214561A1 (uk)
EP (1) EP2114405B1 (uk)
JP (1) JP4799666B2 (uk)
KR (1) KR101130146B1 (uk)
CN (1) CN101573114A (uk)
AR (1) AR064545A1 (uk)
AU (1) AU2007341356B2 (uk)
BR (1) BRPI0720829B8 (uk)
CA (1) CA2673667A1 (uk)
CL (1) CL2007003830A1 (uk)
CO (1) CO6190613A2 (uk)
CR (1) CR10846A (uk)
CY (1) CY1116350T1 (uk)
DK (1) DK2114405T3 (uk)
EC (1) ECSP099471A (uk)
ES (1) ES2535040T3 (uk)
HR (1) HRP20150573T1 (uk)
HU (1) HUE025032T2 (uk)
MA (1) MA31029B1 (uk)
MX (1) MX2009006859A (uk)
MY (1) MY188367A (uk)
NO (1) NO342150B1 (uk)
NZ (1) NZ577502A (uk)
PE (1) PE20081556A1 (uk)
PL (1) PL2114405T3 (uk)
PT (1) PT2114405E (uk)
RS (1) RS53910B1 (uk)
RU (1) RU2463295C2 (uk)
SI (1) SI2114405T1 (uk)
TW (1) TWI388552B (uk)
UA (1) UA100232C2 (uk)
WO (1) WO2008080821A1 (uk)
ZA (1) ZA200904423B (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2114405E (pt) 2006-12-28 2015-06-02 Hoffmann La Roche Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona
US8586587B2 (en) 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
CN104334550A (zh) * 2012-05-25 2015-02-04 巴斯夫欧洲公司 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
CN116212025A (zh) 2020-01-09 2023-06-06 迪斯克医药公司 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法
JP2024518091A (ja) * 2021-05-14 2024-04-24 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて赤血球増殖性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球増殖性ポルフィリン症を処置する方法
WO2022251458A1 (en) * 2021-05-27 2022-12-01 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
SI1656361T1 (sl) * 2003-08-11 2008-04-30 Hoffmann La Roche Piperazin z OR-substituirano fenilno skupino in njuna uporaba kot zaviralca GLYT1
PT2114405E (pt) 2006-12-28 2015-06-02 Hoffmann La Roche Forma co-cristalina de metil-parabeno ¿a¿ - [4- (3-fluor-5-trifluormetil-piridin-2-il)-piperazin- 1-il]-[5-metano-sulfonil-2-((s)-2,2,2-trifluoro-1- metil-etoxi)-fenil]-metanona

Also Published As

Publication number Publication date
CA2673667A1 (en) 2008-07-10
TW200833677A (en) 2008-08-16
CO6190613A2 (es) 2010-08-19
DK2114405T3 (en) 2015-04-07
RS53910B1 (en) 2015-08-31
ES2535040T3 (es) 2015-05-04
MA31029B1 (fr) 2009-12-01
ECSP099471A (es) 2009-07-31
BRPI0720829B1 (pt) 2020-04-07
MX2009006859A (es) 2009-07-03
KR101130146B1 (ko) 2012-03-28
US20130197225A1 (en) 2013-08-01
KR20090094166A (ko) 2009-09-03
US8039473B2 (en) 2011-10-18
RU2009124113A (ru) 2011-02-10
US20110295007A1 (en) 2011-12-01
AU2007341356A1 (en) 2008-07-10
HRP20150573T1 (en) 2015-07-03
TWI388552B (zh) 2013-03-11
JP4799666B2 (ja) 2011-10-26
JP2010514725A (ja) 2010-05-06
AR064545A1 (es) 2009-04-08
MY188367A (en) 2021-12-06
NZ577502A (en) 2012-02-24
CL2007003830A1 (es) 2008-07-11
RU2463295C2 (ru) 2012-10-10
US20100311971A1 (en) 2010-12-09
US20120309969A1 (en) 2012-12-06
HUE025032T2 (en) 2016-02-29
CY1116350T1 (el) 2017-03-15
WO2008080821A1 (en) 2008-07-10
US20080214561A1 (en) 2008-09-04
PT2114405E (pt) 2015-06-02
CR10846A (es) 2009-08-12
BRPI0720829B8 (pt) 2021-05-25
PL2114405T3 (pl) 2015-08-31
BRPI0720829A2 (pt) 2014-02-25
NO342150B1 (no) 2018-04-03
NO20092358L (no) 2009-06-22
EP2114405B1 (en) 2015-03-11
PE20081556A1 (es) 2008-11-28
SI2114405T1 (sl) 2015-06-30
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
ZA200904423B (en) 2010-05-26
CN101573114A (zh) 2009-11-04

Similar Documents

Publication Publication Date Title
UA100232C2 (uk) Кристалічні форми інгібітора glyt1
MXPA06002727A (es) Derivados de 1-(2-amino-benzol)-piperazina como inhibidores de la captacion de glicina para el tratamiento de psicosis.
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MY145356A (en) Piperzine with or-substitution for glyt1
MX2009011830A (es) Compuestos amino-heterociclicos.
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
CU20110106A7 (es) Nuevos compuestos 578
TW200633957A (en) Compounds
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
NZ593279A (en) Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
IL198926A0 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
TW200714282A (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
WO2005095348A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2005097114A3 (en) Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
GB0428232D0 (en) Compounds
MX2010008239A (es) 2-aminoquinolinas.
ATE472538T1 (de) 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden
WO2006039767A8 (en) Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes
IN2009CN03566A (uk)
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2007080159A3 (en) Pyridine-, isoxazole, thiophenecarboxamide compounds having activity at the glycine transporter glyt1 and uses thereof
DE602005012826D1 (de) Neue mao-b-hemmer